Treatment of pulmonary hypertension

Rajendrakumar Patel; Wilbert S. Aronow; Laxeshkumar Patel; Kaushang Gandhi; Harit Desai; Dhiraj Kaul; Sumir P. Sahgal

doi:10.12659/MSM.882607

Treatment of pulmonary hypertension

Rajendrakumar Patel, Wilbert S. Aronow, Laxeshkumar Patel, Kaushang Gandhi, Harit Desai, Dhiraj Kaul, Sumir P. Sahgal

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Pulmonary arterial hypertension (PAH) is a chronic progressive disease of the pulmonary vasculature characterized by elevated pulmonary arterial pressure and secondary right ventricular failure. PAH is considered a life-threatening condition unless treated. This article provides a comprehensive review of controlled and uncontrolled trials to define the risk-benefit for different therapeutic options of this clinical disorder. Relevant published articles were identified through searches of the National Center for Biotechnology PubMed database. All therapeutic measures for PAH were discussed. Six drugs have been approved in the United States for the treatment of PAH. Extensive medical advancement has been achieved in treatment of PAH. However, none of the approved therapies have shown ability to cure the disease. New research should be performed to develop promising new therapies.

Original language	English
Pages (from-to)	RA31-RA39
Journal	Medical Science Monitor
Volume	18
Issue number	4
DOIs	https://doi.org/10.12659/MSM.882607
State	Published - 2012
Externally published	Yes

Keywords

Calcium channel blockers
Endothelin receptor antagonists
Lung transplantation
Phosphodiesterase-5 inhibitors
Prostanoids
Pulmonary arterial hypertension

Access to Document

10.12659/MSM.882607

Cite this

@article{1c8b588c3bd540969218a01d8d84f069,

title = "Treatment of pulmonary hypertension",

abstract = "Pulmonary arterial hypertension (PAH) is a chronic progressive disease of the pulmonary vasculature characterized by elevated pulmonary arterial pressure and secondary right ventricular failure. PAH is considered a life-threatening condition unless treated. This article provides a comprehensive review of controlled and uncontrolled trials to define the risk-benefit for different therapeutic options of this clinical disorder. Relevant published articles were identified through searches of the National Center for Biotechnology PubMed database. All therapeutic measures for PAH were discussed. Six drugs have been approved in the United States for the treatment of PAH. Extensive medical advancement has been achieved in treatment of PAH. However, none of the approved therapies have shown ability to cure the disease. New research should be performed to develop promising new therapies.",

keywords = "Calcium channel blockers, Endothelin receptor antagonists, Lung transplantation, Phosphodiesterase-5 inhibitors, Prostanoids, Pulmonary arterial hypertension",

author = "Rajendrakumar Patel and Aronow, {Wilbert S.} and Laxeshkumar Patel and Kaushang Gandhi and Harit Desai and Dhiraj Kaul and Sahgal, {Sumir P.}",

note = "Funding Information: AMA reports funding for a pulmonary hypertension registry at King Faisal Specialist Hospital from Actelion, outside of this Review. NG and MMH received personal fees from Actelion, Bayer, GSK, and Pfizer. VVM received grants and personal fees from Actelion, Bayer, Gilead, Ikaria, and United Therapeutics, and grants from Novartis. TS received personal fees from Actelion. This Review is independent of any influence from pharmaceutical companies and has been written by the authors without any third-party support. ",

year = "2012",

doi = "10.12659/MSM.882607",

language = "English",

volume = "18",

pages = "RA31--RA39",

journal = "Medical Science Monitor",

issn = "1234-1010",

publisher = "International Scientific Literature Inc.",

number = "4",

}

TY - JOUR

T1 - Treatment of pulmonary hypertension

AU - Patel, Rajendrakumar

AU - Aronow, Wilbert S.

AU - Patel, Laxeshkumar

AU - Gandhi, Kaushang

AU - Desai, Harit

AU - Kaul, Dhiraj

AU - Sahgal, Sumir P.

N1 - Funding Information: AMA reports funding for a pulmonary hypertension registry at King Faisal Specialist Hospital from Actelion, outside of this Review. NG and MMH received personal fees from Actelion, Bayer, GSK, and Pfizer. VVM received grants and personal fees from Actelion, Bayer, Gilead, Ikaria, and United Therapeutics, and grants from Novartis. TS received personal fees from Actelion. This Review is independent of any influence from pharmaceutical companies and has been written by the authors without any third-party support.

PY - 2012

Y1 - 2012

N2 - Pulmonary arterial hypertension (PAH) is a chronic progressive disease of the pulmonary vasculature characterized by elevated pulmonary arterial pressure and secondary right ventricular failure. PAH is considered a life-threatening condition unless treated. This article provides a comprehensive review of controlled and uncontrolled trials to define the risk-benefit for different therapeutic options of this clinical disorder. Relevant published articles were identified through searches of the National Center for Biotechnology PubMed database. All therapeutic measures for PAH were discussed. Six drugs have been approved in the United States for the treatment of PAH. Extensive medical advancement has been achieved in treatment of PAH. However, none of the approved therapies have shown ability to cure the disease. New research should be performed to develop promising new therapies.

AB - Pulmonary arterial hypertension (PAH) is a chronic progressive disease of the pulmonary vasculature characterized by elevated pulmonary arterial pressure and secondary right ventricular failure. PAH is considered a life-threatening condition unless treated. This article provides a comprehensive review of controlled and uncontrolled trials to define the risk-benefit for different therapeutic options of this clinical disorder. Relevant published articles were identified through searches of the National Center for Biotechnology PubMed database. All therapeutic measures for PAH were discussed. Six drugs have been approved in the United States for the treatment of PAH. Extensive medical advancement has been achieved in treatment of PAH. However, none of the approved therapies have shown ability to cure the disease. New research should be performed to develop promising new therapies.

KW - Calcium channel blockers

KW - Endothelin receptor antagonists

KW - Lung transplantation

KW - Phosphodiesterase-5 inhibitors

KW - Prostanoids

KW - Pulmonary arterial hypertension

UR - http://www.scopus.com/inward/record.url?scp=84859544966&partnerID=8YFLogxK

U2 - 10.12659/MSM.882607

DO - 10.12659/MSM.882607

M3 - Article

AN - SCOPUS:84859544966

SN - 1234-1010

VL - 18

SP - RA31-RA39

JO - Medical Science Monitor

JF - Medical Science Monitor

IS - 4

ER -

Treatment of pulmonary hypertension

Abstract

Keywords

Access to Document

Fingerprint

Cite this